Paragraph IV Certification Notice, Month Stay Period

No definition available.

Name:	amag_ParagraphIVCertificationNoticeMonthStayPeriod
Namespace Prefix:	amag_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the period of time in during which a patent infringement suit can be filed in federal district court after receipt of the Paragraph IV certification.

+ References

No definition available.

+ Details

Name:	amag_ParagraphIvCertificationNoticeTimePeriodDuringWhichPatentInfringementSuitCanBeFiled
Namespace Prefix:	amag_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Research and Development Asset Acquired Other Than Through Business Combination, Future Contingent Payments

+ References

No definition available.

+ Details

Name:	amag_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationFutureContingentPayments
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Research And Development Asset Acquired Other Than Through Business Combination, Royalty Percentage

+ References

No definition available.

+ Details

Name:	amag_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationRoyaltyPercentage
Namespace Prefix:	amag_
Data Type:	num:percentItemType
Balance Type:	na
Period Type:	instant

- Definition

Research And Development Asset Acquired Other Than Through Business Combination, Threshold For Future Contingent Payments

+ References

No definition available.

+ Details

Name:	amag_ResearchAndDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationThresholdForFutureContingentPayments
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Research And Development Asset Acquired Other than Through Business Combination, Period After Sale

+ References

No definition available.

+ Details

Name:	amag_ResearchAndDevelopmentAssetAcquiredOtherthanThroughBusinessCombinationPeriodAfterSale
Namespace Prefix:	amag_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Research and Development Asset Acquired Other Than Through Business Combination, Sales Milestone

+ References

No definition available.

+ Details

Name:	amag_ResearchandDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationSalesMilestone
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Research and Development Asset Acquired Other Than Through Business Combination, Sales Milestone Threshold

+ References

No definition available.

+ Details

Name:	amag_ResearchandDevelopmentAssetAcquiredOtherThanThroughBusinessCombinationSalesMilestoneThreshold
Namespace Prefix:	amag_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

No definition available.

+ Details

Name:	us-gaap_LossContingenciesLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_LossContingenciesByNatureOfContingencyAxis=amag_SandozPatentInfringementLawsuitMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=amag_EndoceuticsLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationFirstSalesMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	dei_LegalEntityAxis=amag_EndoceuticsInc.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationSecondSalesMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationThirdSalesMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationTieredRoyaltiesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=amag_PalatinLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ContingentConsiderationByTypeAxis=amag_ContingentConsiderationRegulatoryMilestoneAchievementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Details) - USD ($)		1 Months Ended	6 Months Ended
Commitments and Contingencies (Details) - USD ($)	Feb. 05, 2016	Mar. 31, 2016	Jun. 30, 2017
Sandoz Patent Infringement Lawsuit
Commitments
Period of time, patent infringement suit can be filed in federal district court (in days)	45 days
Month stay period (in months)	30 months	30 months
Endoceutics License Agreement
Commitments
Period after first commercial sale (in years)			10 years
Endoceutics License Agreement \| First Sales Milestone \| Endoceutics, Inc.
Commitments
Sales milestone			$ 15,000,000.0
Sales milestone, triggering amount			150,000,000.0
Endoceutics License Agreement \| Second Sales Milestone \| Endoceutics, Inc.
Commitments
Sales milestone			30,000,000.0
Sales milestone, triggering amount			300,000,000.0
Endoceutics License Agreement \| Third Sales Milestone \| Endoceutics, Inc.
Commitments
Sales milestone			850,000,000.0
Sales milestone, triggering amount			500,000,000.0
Endoceutics License Agreement \| Tiered Royalties
Commitments
Maximum future contingent payments			150,000,000.0
Net sales threshold, future contingent payments			$ 1,000,000,000.0
Endoceutics License Agreement \| Tiered Royalties \| Maximum
Commitments
Royalty percentage, maximum			20.00%
Palatin License Agreement \| License Agreement Terms
Commitments
Maximum future contingent payments			$ 380,000,000.0
Palatin License Agreement \| First Sales Milestone \| License Agreement Terms
Commitments
Sales milestone			25,000,000.0
Sales milestone, triggering amount			250,000,000.0
Maximum future contingent payments			300,000,000.0
Palatin License Agreement \| Regulatory milestone \| License Agreement Terms
Commitments
Maximum future contingent payments			$ 80,000,000.0